345 related articles for article (PubMed ID: 37077823)
1. UPS: Opportunities and challenges for gastric cancer treatment.
Yang H; Ai H; Zhang J; Ma J; Liu K; Li Z
Front Oncol; 2023; 13():1140452. PubMed ID: 37077823
[TBL] [Abstract][Full Text] [Related]
2. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.
Qi SM; Dong J; Xu ZY; Cheng XD; Zhang WD; Qin JJ
Front Pharmacol; 2021; 12():692574. PubMed ID: 34025443
[TBL] [Abstract][Full Text] [Related]
3. The role of E3 ubiquitin ligases in bone homeostasis and related diseases.
Dong Y; Chen Y; Ma G; Cao H
Acta Pharm Sin B; 2023 Oct; 13(10):3963-3987. PubMed ID: 37799379
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Lospinoso Severini L; Bufalieri F; Infante P; Di Marcotullio L
Front Cell Dev Biol; 2022; 10():854352. PubMed ID: 35242765
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
7. [Intermolecular interaction-based ubiquitin-proteasome system-targeting drug discovery].
Naito M; Komatsu H
Nihon Yakurigaku Zasshi; 2021; 156(1):9-12. PubMed ID: 33390482
[TBL] [Abstract][Full Text] [Related]
8. PROTACs in gastrointestinal cancers.
Chen Y; Yang Q; Xu J; Tang L; Zhang Y; Du F; Zhao Y; Wu X; Li M; Shen J; Ding R; Cao H; Li W; Li X; Chen M; Wu Z; Cho CH; Du Y; Wen Q; Xiao Z
Mol Ther Oncolytics; 2022 Dec; 27():204-223. PubMed ID: 36420306
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
10. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
11. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
12. Degradation of proteins by PROTACs and other strategies.
Wang Y; Jiang X; Feng F; Liu W; Sun H
Acta Pharm Sin B; 2020 Feb; 10(2):207-238. PubMed ID: 32082969
[TBL] [Abstract][Full Text] [Related]
13. Designing HDAC-PROTACs: lessons learned so far.
Fischer F; Alves Avelar LA; Murray L; Kurz T
Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
[TBL] [Abstract][Full Text] [Related]
14. E3 ligase ligand optimization of Clinical PROTACs.
Jiang H; Xiong H; Gu SX; Wang M
Front Chem; 2023; 11():1098331. PubMed ID: 36733714
[TBL] [Abstract][Full Text] [Related]
15. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
16. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
17. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.
Wang H; Lu Y; Wang M; Wu Y; Wang X; Li Y
J Mol Med (Berl); 2021 Feb; 99(2):193-212. PubMed ID: 33392633
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.
Cecchini C; Tardy S; Ceserani V; Theurillat JP; Scapozza L
Chimia (Aarau); 2020 Apr; 74(4):274-277. PubMed ID: 32331546
[TBL] [Abstract][Full Text] [Related]
19. E2-E3 ubiquitin enzyme pairing - partnership in provoking or mitigating cancers.
Chang SC; Zhang BX; Ding JL
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188679. PubMed ID: 35074437
[TBL] [Abstract][Full Text] [Related]
20. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
